Ne

News

Body and Mind Provides California Update

VANCOUVER, B.C., CANADA (December 5, 2019) – Body and Mind Inc. (CSE: BAMM, OTCQB: BMMJ) (the “Company” or “BaM”), a multi-state cannabis company with operations in California, Nevada, Arkansas, and Ohio, is pleased to provide an update on California operations including construction updates in San Diego, Marijuana Enforcement Tracking Compliance (“METRC”) at ShowGrow Long Beach […]

Body and Mind Appoints Brent Reuter to Board of Directors

VANCOUVER, B.C., CANADA (October 21, 2019) – Body and Mind Inc. (CSE: BAMM, OTCQB: BMMJ) (the “Company” or “BaM”) a multi-state operator is pleased to announce that Brent Reuter has been appointed to the Board of Directors as Australis Capital Inc.’s nominee on the Board of Directors and replaces Scott Dowty who has resigned from […]

Body and Mind Announces Arkansas Dispensary Construction Update and Presentation at Benzinga Capital Conference in Chicago

VANCOUVER, B.C., CANADA (October 17, 2019) – Body and Mind Inc. (CSE: BAMM, OTCQB: BMMJ) (the “Company” or “BaM”) a multi-state operator, is pleased to update shareholders on the construction of its fully funded medical marijuana dispensary in West Memphis, Arkansas. The facility is being developed with its in-state partner, Comprehensive Care Group LLC (“CCG”). […]

Body and Mind Appoints David Wenger to Board

VANCOUVER, B.C., CANADA (October 2, 2019) – Body and Mind Inc. (CSE: BAMM, OTCQB: BMMJ) (the “Company” or “BaM”) a multi-state operator is pleased to announce the appointment of David Wenger to the Board of Directors. “I’m excited to have David bring his deep industry and capital markets experience to our board as well as […]

rfwbs-sliderfwbs-sliderfwbs-slide

Qualifying Conditions

  • Cancer
  • Glaucoma
  • Positive status for human immunodeficiency virus/acquired immune deficiency syndrome
  • Hepatitis C
  • Amyotrophic lateral sclerosis
  • Tourette’s syndrome
  • Crohn’s disease
  • Ulcerative colitis
  • Post-traumatic stress disorder
  • Severe arthritis
  • Fibromyalgia
  • Alzheimer’s disease
  • Cachexia or wasting syndrome
  • Peripheral neuropathy
  • Intractable pain which is pain that has not responded to ordinary medications, treatment or surgical measures for more than six (6) months
  • Severe nausea
  • Seizures including without limitation those characteristic of epilepsy
  • Severe and persistent muscle spasms including without limitation those characteristic of multiple sclerosis and any other medical condition or its treatment approved by the Department of Health.